The common stock is listed on the Nasdaq Global Select Market

Davis Polk advised the underwriter of a public offering of 10,869,566 shares of common stock of Alector, Inc. for total gross proceeds of approximately $75 million. The underwriter has been granted an option to purchase up to additional 1,630,434 shares. Alector’s common stock is listed on the Nasdaq Global Select Market under the symbol “ALEC.”

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Sarah Catherine Chouinard and Alex Moss. Partner David R. Bauer and associate Gabrielle Mazero provided intellectual property advice. Partner Patrick E. Sigmon and associate Alanna Phillips provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post